Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

A highly collaborative investment professional and US software research analyst with 10+ years of international experience in equity research, treasury operations, and trading positions across multiple asset classes at leading multinational banks Citibank and Morgan Stanley, UHNWI-backed family office and European independent equity research firm. A respectable background in equity capital markets, corporate treasury, investment banking operations, equity research analysis and portfolio management.

Inari Medical: Innovative Devices For the Treatment of Venous Diseases

Algosun Global

Equity Bottom-Up

<ul>
<li>We downgrade <a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a> shares to <strong>Neutral</strong> and lower a price target to <strong>$83.00</strong>, implying a ~4% upside. </li>
<li>We see limited upside to <a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a>  shares due to peer-group multiple compression, slow expansion in Europe and Asia, and rising operating expenses.</li>
<li>
<a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a> completed SPO, issued 2.3M shares, and raised ~$174M to strengthen the balance sheet in 1Q22.  </li>
</ul>


We downgrade Inari Medical (NARI US) shares to Neutral and lower a price target to $83.00, implying a ~4% upside. 
We see limited upside to Inari Medical (NARI US)  shares due to peer-group multiple compression, slow expansion in Europe and Asia, and rising operating expenses.

Inari Medical (NARI US) completed SPO, issued 2.3M shares, and raised ~$174M to strengthen the balance sheet in 1Q22.  


Inari Medical. Company Update: Downgrade To Neutral